GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

Completed

• Conditions: Type 1 Diabetes
• Interventions: Other: radiolabeled Exendin

• Registration Number: NCT01825148
• Lead Sponsor: Radboud University Medical Center

Brief Summary

The purpose of the study is to determine whether there are differences in pancreatic uptake of the radiotracer between healthy individuals and patients with type 1 diabetes. If T1D patients have a markedly reduced uptake, the compound may be suitable for estimation of pancreatic beta cell mass, i.e. the cells in the pancreas that produce insulin.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-12
• Study First Submitted: 2013-03-18
• Study First Submitted QC: 2013-04-02
• Study First Posted: 2013-04-05
• Primary Completion: 2014-05
• Study Completion: 2014-05
• Status Verified: 2014-11
• Last Update Submitted: 2014-11-27
• Last Update Posted: 2014-12-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• type 1 Diabetes

Read More

Exclusion Criteria

• breast feeding
• pregnant

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Healthy volunteer	radiolabeled Exendin	healthy volunteers with normal glucose tolerance
Type 1 Diabetes	radiolabeled Exendin	patients with long standing T1D

Primary Outcome Measures

Name	Time	Method
pancreatic uptake of radiolabeled Exendin	7 days	uptake will be given as counts per MBq injected activity as determined by calibrated SPECT/CT scanner with attenuation correction.

Trial Locations

Locations (1)

Radboud University Nijmegen Medical Center; 🇳🇱 Nijmegen, Gelderland, Netherlands